Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders

Bhutani, Manisha; Shahid, Zainab; Schnebelen, Alicia M.; Alapat, Daisy; Usmani, Saad Z.

doi:10.1053/j.seminoncol.2016.02.017

Cited by 22 publications

(22 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In multiple myeloma, the neoplastic PCs are dependent on the bone marrow microenvironment for survival and growth . Hence, extramedullary involvement is uncommon . The skin is affected in less than 2% cases, usually late in the course of the disease when the tumor burden is heavy.…”

Section: Plasmacytic Infiltrates In the Skin—neoplasticmentioning

confidence: 99%

See 1 more Smart Citation

Plasmacytic cutaneous pathology: A review

et al. 2019

View full text Add to dashboard Cite

We review the spectrum of cutaneous disorders associated with inflammatory and neoplastic plasmacytic pathology. Because plasma cells are derived from B‐lymphocytes our overview includes discussion of certain lymphoplasmacytic proliferations. It is structured along histopathological lines, addressing conditions characterized by (a) cutaneous plasma cell infiltrates, (b) deposits of plasma cell products or their derivatives in the skin and (c) miscellaneous, poorly understood cutaneous complications of plasmacytic disorders. Lesions arising primarily in the skin and those due to cutaneous involvement by multisystem disorders are addressed. The range includes a spectrum of tumefactive and circulatory manifestations. We highlight key clinical and pathological features of the different conditions and outline recent advances in our understanding of these entities. By emphasizing the dermatopathological characteristics of this spectrum of disorders we hope to hone the diagnostic accuracy of practitioners in the field.

show abstract

Section: Plasmacytic Infiltrates In the Skin—neoplasticmentioning

confidence: 99%

“…18 Hence, extramedullary involvement is uncommon. [19][20][21] The skin is affected in less than 2% cases, usually late in the course of the disease when the tumor burden is heavy. Most affected patients die within months.…”

Section: Introductionmentioning

confidence: 99%

Plasmacytic cutaneous pathology: A review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Bu plazma hücre diskrazilerinden biri anormal plazma hücre proliferasyonuyla seyreden multipl miyelom (MM)'dur. 3,4 Bu çalışmada, deri bulguları ile tanı konan primer sistemik amiloidoz ve MM olgusunun sunulması amaçlanmıştır. TARTIŞMA Amiloidoz, dokuda ve organlarda amiloid fibrillerin depolanmasıyla karakterizedir ve primer olabileceği gibi altta yatan birçok hastalık nedeni ile de oluşabilir.…”

unclassified

“…Histolojik teşhis koyulduktan sonra, amiloid proteininin alt tipi immünohistokimyasal olarak veya kütle spektroskopisi ile belirlenir. 4,9 Tedavide sistemik ve topikal kortikosteroidler, alkilleyici ajanlar (Melfalan) ve immünmodülatörler (Talidomid), bortezomib gibi proteozom inhibitörleri ve otolog veya allojenik kök hücre transplantasyonu uygun vakalarda kullanılır. 1,3,9 Olgumuza da hematoloji tarafından bortezomid ve deksametazon tedavisi başlanmıştı fakat hasta 2 kür tedavi alabildi.…”

unclassified

A Case of Systemic Amyloidosis Associated with Multiple Myeloma Diagnosed with Skin Findings

Erdem¹,

Gönül²,

Ateş³

et al. 2020

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

“…Myeloma skin manifestations are uncommon, heterogeneous, and usually a late phenomenon. They may occur through a known mechanism, for example, direct skin involvement by malignant plasma cells, tissue deposition or immunoglobulin biological activity or through unknown mechanisms …”

mentioning

confidence: 99%